2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, D. H. Articles by Brown, J. B. Search for Related Content PubMed PubMed Citation Articles by Smith, D. H. Articles by Brown, J. B.

Cost of Medical Care for Chronic Kidney Disease and Comorbidity among Enrollees in a Large HMO Population

David H. Smith^*,, Christina M. Gullion^*, Gregory Nichols^*, Douglas Scott Keith and Jonathan Betz Brown^*

*Kaiser Permanente Center for Health Research, Portland, Oregon; University of Washington School of Pharmacy, Portland Oregon; Kaiser Permanente Northwest Region, Department of Nephrology, Portland Oregon.

Correspondence to Dr. David H. Smith, Investigator, Kaiser Permanente Center for Health Research, 3800 N Interstate Ave, Portland, OR 97211. Phone: 503-335-6302; Fax: 503-335-2428; E-mail david.h.smith{at}kpchr.org

ABSTRCT. Chronic kidney disease (CKD) afflicts up to 20 million people in the United States, but little is known about their health care costs. The authors analyzed costs and resource use associated with CKD by using National Kidney Foundation staging definitions. Patients insured through a large health maintenance organization with a laboratory finding of CKD (defined as estimated GFR between 15 and 90 ml/min per 1.73 m² in 1996 followed by a second GFR below 90 at the next creatinine measurement occurring at least 90 d later) were followed from 1996 for up to 66 mo. The final cohort included 13,796 persons with CKD and their age- and gender-matched controls; 1741 in stage 2; 11,278 in stage 3; and 777 in stage 4. Depending on stage, cases had 1.9 to 2.5 times more prescriptions, 1.3 to 1.9 times more outpatient visits, were 1.6 to 2.2 times more likely to have had an inpatient stay, and had 1.8 to 3.1 more stays than did controls. Total per patient follow-up costs were [$total, (95% CI) cases and controls, respectively] $38,764 (95% CI, 37,033 to $40,496) and $16,212 (95% CI, $15,644 to $16,780) in stage 2; $33,144 (95% CI, $32,578 to $33,709) and $18,964 (95% CI, $18,730 to $19,197) in stage 3; and $41,928 (95% CI, $39,354 to $44,501) and $19,106 (95% CI, $18,212 to $20,000) in stage 4. Cases with no CKD-related comorbidities had costs double that of controls with no CKD-related comorbidities, and comorbidities related to CKD were more costly to manage than CKD alone. Future research in this area could be usefully directed toward analyzing the clinical and economic consequences of better managing or preventing comorbidities in patients with CKD.

This article has been cited by other articles:

				A. Meyer, H. Bunzemeier, M. Hausberg, M. Walter, N. Roeder, G. Breithardt, and H. Reinecke Impact of different stages of chronic kidney disease on in-hospital costs in patients with coronary heart disease Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1955 - 1960. [Abstract] [Full Text] [PDF]

				F. W Maddux, S. Shetty, M. A del Aguila, M. A Nelson, and B. M Murray Effect of Erythropoiesis-Stimulating Agents on Healthcare Utilization, Costs, and Outcomes in Chronic Kidney Disease Ann. Pharmacother., November 1, 2007; 41(11): 1761 - 1769. [Abstract] [Full Text] [PDF]

				J. Tomlinson How Do We Re-Design the Treatment?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix39 - ix44. [Full Text] [PDF]

				T. C. Dowling Introduction Am. J. Health Syst. Pharm., July 1, 2007; 64(13_Supplement_8): S2 - S2. [Full Text] [PDF]

				T. C. Dowling Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: An overview Am. J. Health Syst. Pharm., July 1, 2007; 64(13_Supplement_8): S3 - S7. [Abstract] [Full Text] [PDF]

				L. A. Stevens, G. Fares, J. Fleming, D. Martin, K. Murthy, J. Qiu, P. C. Stark, K. Uhlig, F. Van Lente, and A. S. Levey Low Rates of Testing and Diagnostic Codes Usage in a Commercial Clinical Laboratory: Evidence for Lack of Physician Awareness of Chronic Kidney Disease J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2439 - 2448. [Abstract] [Full Text] [PDF]

				D. C. Mendelssohn Coping with the CKD epidemic: the promise of multidisciplinary team-based care Nephrol. Dial. Transplant., January 1, 2005; 20(1): 10 - 12. [Full Text] [PDF]

				L. G. Hunsicker The Consequences and Costs of Chronic Kidney Disease Before ESRD J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1363 - 1364. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673